Developer docs
API playgroundTry for free, no card

Search company profiles

Cleo Diagnostics

Full company profile

uuid0009jvs

Namestring
Cleo Diagnostics
Legal namestring
Cleo Diagnostics Limited
Websiteurl
cleodx.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Cleo Diagnostics Limited is an Australian molecular diagnostics company developing a portfolio of blood tests for the detection and management of ovarian cancer, with its core product being the CleoDX Pre-Surgical Triage Test branded AdnexaSure™. The test is a multi-marker immunoassay built on the CXCL10 biomarker — exclusively licensed worldwide from the Hudson Institute of Medical Research following 15+ years of academic research — combined with CA125, HE4, IL6 and additional markers, recently expanded from a 5-biomarker to an 8-biomarker panel. The assay is designed to run on Bio-Techne's Ella™ automated ELISA microfluidic platform, which delivers a 90-minute total run time and simultaneous measurement of multiple biomarkers per patient sample. The intended use is to distinguish benign from malignant ovarian/adnexal masses prior to surgery, addressing the documented failure of the current CA125-plus-ultrasound standard of care, which misses roughly half of early-stage cancers and generates substantial false-positive referrals.

The company has not yet generated commercial revenue and is pre-market, with US FDA 510(k) clearance being the gating commercial milestone. Its go-to-market motion is sales-led, targeting US gynaecologic oncologists, surgeons, and clinical pathology laboratories through standard blood-test ordering workflows, supported by Key Opinion Leader engagement (Dr Nicholas Lambrou appointed as the first US KOL in November 2025) and outsourced US market access via HcFocus. A lean operating model of 1-10 employees relies on partners for clinical trial execution (Lindus Health), biobank validation sample access (UCL/UKCTOCS and NCI/PLCO), antibody manufacturing scale-up (R&D Systems, a Bio-Techne subsidiary), health economics (EntityRisk), and payer intelligence (Norstella). Cleo is publicly listed on the ASX (ticker: COV) since 22 August 2023, headquartered at Level 2, 480 Collins Street, Melbourne, Australia, with no parent company and no controlling shareholder identified in the source material.

The product pipeline extends beyond pre-surgical triage to include ovarian cancer recurrence monitoring, a high-risk population test (BRCA mutation carriers and women with family history), and a long-term mass screening test, staged in increasing addressable market size and development risk. The first commercial product is positioned for a US pre-surgical triage addressable market of approximately 2.0 million women per year, identified via Norstella physician-and-claims data analysis. Capital structure as of late 2025 includes approximately A$5.75 million in cash (post A$1.7M R&D tax incentive refund and a A$5M December 2025 placement led by Petra Capital), with use of proceeds funding US commercial launch activities, reimbursement workstreams and screening-test development.

Short descriptiontext

Cleo Diagnostics is an Australian molecular diagnostics company developing AdnexaSure™, a multi-marker blood test for early and accurate ovarian cancer detection, currently pursuing FDA 510(k) clearance for US launch via pathology laboratory and gynaecologic-oncology channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ovarian cancer diagnostics, blood test diagnostics, in-vitro diagnostics, cancer biomarker testing, pre-surgical triage test
Industry1 code
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Ovarian Cancer Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Test Kits
TypeOne Time License
Description

Cleo's first commercial product (AdnexaSure™) is a blood test kit sold to pathology laboratories and ordered by physicians. Revenue is generated through sale of diagnostic test kits to clinical laboratories following regulatory approval. Pathology providers perform the test and return results to physicians. US market launch is planned following FDA 510(k) clearance.

cleodx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AdnexaSure
Description

CLEO's first test - AdnexaSure is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.

cleodx.com
Core offering1 text field

Cleo Diagnostics is developing and commercialising a proprietary blood-based diagnostic test (AdnexaSure™) for the early and accurate detection of ovarian cancer. The test uses the CXCL10 active ratio combined with additional biomarkers to generate a Risk of Malignancy score that distinguishes benign from malignant adnexal masses prior to surgery. The test is designed to be ordered and processed through standard clinical pathology laboratory workflows using the Bio-Techne Ella™ automated ELISA platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 90% early-stage (Stage I/II) cancer detection vs 50% with standard CA125+ultrasound workflows
+5 more records
Product overview1 text field

Cleo Diagnostics is developing a portfolio of ovarian cancer blood tests based on its patented CXCL10 biomarker technology. The core product is the CleoDX Pre-Surgical Triage Test (AdnexaSure™), a CE-marked/FDA-cleared blood test that distinguishes benign from malignant ovarian masses prior to surgery. The technology platform uses a proprietary algorithm combining the CXCL10 active ratio with multiple biomarkers (CA125, HE4, IL6) to generate Risk of Malignancy scores. CLEO's staged execution strategy encompasses multiple test products: the initial pre-surgical triage market, followed by recurrence monitoring and high-risk population tests, ultimately leading to an early-stage screening test for general population detection.

Product and service1 record
1AdnexaSure™ Pre-Surgical Triage Test
CategoryPre-Surgical Ovarian Cancer Diagnostic Test Kit (IVD)
Description

A blood test (IVD kit) designed to accurately distinguish benign from malignant ovarian growths prior to surgical intervention. The test measures the CXCL10 active ratio combined with biomarkers including CA125, HE4, and IL6, processed on the Bio-Techne Ella™ automated ELISA platform, and returns a Risk of Malignancy score to the referring physician. It is intended for sale to clinical pathology laboratories and ordered by gynaecologists and oncologists.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-18
Description

CLEO selected Bio-Techne's Ella™ automated ELISA platform as the immunoassay instrument for its ovarian cancer blood test. The Ella™ platform uses microfluidic cartridges to measure CLEO's proprietary biomarker panel. Discussions are well progressed for a binding agreement for analytical validation. Both parties are aligned to enter a long-term manufacturing supply agreement following completion of validation activities. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025.

Strategic tierKeyTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-18
Description

Specialist in health economics and value modelling engaged to develop a model quantifying the economic benefits of adopting CLEO's Pre-Surgical Test for Ovarian Cancer in the US. The health economic analysis will provide evidence-based justification for payor engagement and reimbursement negotiations.

Strategic tierKeyTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-18
Description

Global pharma intelligence solution provider engaged to examine detailed physician and claims data to identify high-value US launch markets and maximise early adoption potential. Norstella's market access and payer intelligence capabilities (including Managed Markets Insight & Technology/MMIT) inform reimbursement data modelling. Comprehensive analysis delivers refined TAM estimate and payer policy insights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-25
Description

CLEO received formal approval from the US National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial biobank. The PLCO is considered a gold standard resource and one of the largest US longitudinal cancer studies. Samples will be used to generate data strengthening CLEO's FDA 510(k) submission and accelerate development of its screening test.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Collaboration agreement with UCL granted CLEO access to over 2,000 blood samples from the UKCTOCS (United Kingdom Collaborative Trial of Ovarian Cancer Screening), the world's largest ovarian cancer screening trial. Data will be independently analysed in partnership with UCL, providing unbiased validation of CLEO's technology. Partnership with renowned Ovarian Cancer expert Professor Usha Menon supports both pre-surgical and screening market evaluation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-18
Description

R&D Systems, a global leader in immunoassay technology and subsidiary of Bio-Techne Group, was engaged to scale-up and assemble CLEO's proprietary antibodies for use in its initial Ovarian Cancer test targeted at the surgical triage market. The company undertook hybridoma cell line development, antibody production and testing, and reagent selection. This partnership represents the critical technology transfer step from in-house development to commercial-scale production.

7Siles Health
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-12-10
Description

Network of 13 women's health and ultrasound specialist clinics across Melbourne and regional Victoria joined CLEO's Australian ovarian cancer trial, with Associate Professor Charles Siles as Principal Investigator. Partnership aims to provide insights into clinical workflows supporting market adoption and supplement the broader trial strategy.

cleodx.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-11-27
Description

Australia's leading specialist hospital for women's health joined CLEO's ovarian cancer trial as a participating site, with Associate Professor Orla McNally (Director of Oncology and Dysplasia Service) as Principal Investigator. Partnership aims to broaden patient sampling, expand market awareness, verify and optimise the ovarian cancer blood test, and potentially bolster the US trial.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-04-11
Description

US-based Contract Research Organization (CRO) appointed to manage the successful execution of CLEO's ovarian cancer US clinical trials. Lindus Health was chosen for its proven experience, technology, and high standards in med-tech clinical trial management. The study targets up to 500 US patients with trial scheduled over 10 months. Lindus Health leverages innovative patient recruitment and trial management technology platform.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-04-02
Description

New York-based strategic healthcare consultancy appointed to assist with US commercial activities. HcFocus specialises in helping med-tech companies access the US healthcare market, supporting FDA approval, reimbursement with private insurers, clinical trial support, KOL appointments, and industry/doctor engagement. Led by Dr Susan Gross (Ob/GYN), the team brings deep US healthcare industry experience and networks.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets OVA1 and OVERA blood tests for pre-surgical triage of ovarian/adnexal masses — directly comparable to Cleo's AdnexaSure™ in the same indication, customer base (gynaecologists, pathologists) and clinical workflow.

TypeDirect peer
Description

Provides oncology and reproductive-health blood-based diagnostics (Signatera, Empower, Vistara), overlapping with Cleo on biomarker-driven blood tests targeting women's health and oncology specialists.

TypeBroad incumbent
Description

Established hereditary and oncology diagnostics franchise (BRACAnalysis, MyChoice, Prolaris) sold through the same physician and pathology channels Cleo targets, providing both competitive pressure and a benchmark for women's-health oncology commercial models.

TypeBroad incumbent
Description

Commercial leader in non-invasive cancer screening (Cologuard, Oncotype DX) with a broad oncology diagnostics portfolio and US sales infrastructure that could credibly extend into ovarian cancer screening if Cleo's platform proves out.

TypeEmerging player
Description

Liquid-biopsy oncology testing franchise (Guardant360, Reveal) with overlapping biomarker-based blood-test technology and similar physician-channel go-to-market motion, though focused on genomic rather than proteomic signals.

TypeBroad incumbent
Description

Large women's-health diagnostics and medical device company (ThinPrep, NovaSure, Panther molecular system) with established gynaecologist and pathology-lab relationships directly relevant to a pre-surgical ovarian triage launch.

TypeBroad incumbent
Description

Oncology-focused clinical laboratory services business with broad oncologist and pathology-lab relationships; a potential commercial channel and indirect competitor in oncology diagnostics workflows.

8GRAIL
TypeEmerging player
Description

Multi-cancer early-detection blood test (Galleri) pursuing a population-screening indication that is the downstream commercial endpoint of Cleo's stated pipeline strategy.

TypeEmerging player
Description

Multiomics blood-based cancer screening developer with an overlapping biomarker-discovery and clinical-validation approach in oncology diagnostics.

TypeOthers
Description

Technology and manufacturing partner providing the Ella™ automated ELISA platform and antibody production services; not a competitor but a strategic dependency and enabling participant in Cleo's commercial pathway.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cleo Diagnostics

Ovarian Cancer Diagnosticscleodx.com

Cleo Diagnostics is an Australian molecular diagnostics company developing AdnexaSure™, a multi-marker blood test for early and accurate ovarian cancer detection, currently pursuing FDA 510(k) clearance for US launch via pathology laboratory and gynaecologic-oncology channels.

What Cleo Diagnostics does

Cleo Diagnostics Limited is an Australian molecular diagnostics company developing a portfolio of blood tests for the detection and management of ovarian cancer, with its core product being the CleoDX Pre-Surgical Triage Test branded AdnexaSure™. The test is a multi-marker immunoassay built on the CXCL10 biomarker — exclusively licensed worldwide from the Hudson Institute of Medical Research following 15+ years of academic research — combined with CA125, HE4, IL6 and additional markers, recently expanded from a 5-biomarker to an 8-biomarker panel. The assay is designed to run on Bio-Techne's Ella™ automated ELISA microfluidic platform, which delivers a 90-minute total run time and simultaneous measurement of multiple biomarkers per patient sample. The intended use is to distinguish benign from malignant ovarian/adnexal masses prior to surgery, addressing the documented failure of the current CA125-plus-ultrasound standard of care, which misses roughly half of early-stage cancers and generates substantial false-positive referrals.

The company has not yet generated commercial revenue and is pre-market, with US FDA 510(k) clearance being the gating commercial milestone. Its go-to-market motion is sales-led, targeting US gynaecologic oncologists, surgeons, and clinical pathology laboratories through standard blood-test ordering workflows, supported by Key Opinion Leader engagement (Dr Nicholas Lambrou appointed as the first US KOL in November 2025) and outsourced US market access via HcFocus. A lean operating model of 1-10 employees relies on partners for clinical trial execution (Lindus Health), biobank validation sample access (UCL/UKCTOCS and NCI/PLCO), antibody manufacturing scale-up (R&D Systems, a Bio-Techne subsidiary), health economics (EntityRisk), and payer intelligence (Norstella). Cleo is publicly listed on the ASX (ticker: COV) since 22 August 2023, headquartered at Level 2, 480 Collins Street, Melbourne, Australia, with no parent company and no controlling shareholder identified in the source material.

The product pipeline extends beyond pre-surgical triage to include ovarian cancer recurrence monitoring, a high-risk population test (BRCA mutation carriers and women with family history), and a long-term mass screening test, staged in increasing addressable market size and development risk. The first commercial product is positioned for a US pre-surgical triage addressable market of approximately 2.0 million women per year, identified via Norstella physician-and-claims data analysis. Capital structure as of late 2025 includes approximately A$5.75 million in cash (post A$1.7M R&D tax incentive refund and a A$5M December 2025 placement led by Petra Capital), with use of proceeds funding US commercial launch activities, reimbursement workstreams and screening-test development.

Cleo Diagnostics firmographics

Firmographics
Name
Cleo Diagnostics
Legal name
Cleo Diagnostics Limited
Website
https://cleodx.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Cleo Diagnostics is an Australian molecular diagnostics company developing AdnexaSure™, a multi-marker blood test for early and accurate ovarian cancer detection, currently pursuing FDA 510(k) clearance for US launch via pathology laboratory and gynaecologic-oncology channels.
Ownership category
akta.pro rank

Cleo Diagnostics industry classification

Industry
Product category
Ovarian Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)

Keywords

  • Ovarian cancer diagnostics
  • Blood test diagnostics
  • In-vitro diagnostics
  • Cancer biomarker testing
  • Pre-surgical triage test

Where Cleo Diagnostics is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Cleo Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Test Kits: Cleo's first commercial product (AdnexaSure™) is a blood test kit sold to pathology laboratories and ordered by physicians. Revenue is generated through sale of diagnostic test kits to clinical laboratories following regulatory approval. Pathology providers perform the test and return results to physicians. US market launch is planned following FDA 510(k) clearance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cleo Diagnostics product offering

Product offering

Core offering

Cleo Diagnostics is developing and commercialising a proprietary blood-based diagnostic test (AdnexaSure™) for the early and accurate detection of ovarian cancer. The test uses the CXCL10 active ratio combined with additional biomarkers to generate a Risk of Malignancy score that distinguishes benign from malignant adnexal masses prior to surgery. The test is designed to be ordered and processed through standard clinical pathology laboratory workflows using the Bio-Techne Ella™ automated ELISA platform.

Product overview

Cleo Diagnostics is developing a portfolio of ovarian cancer blood tests based on its patented CXCL10 biomarker technology. The core product is the CleoDX Pre-Surgical Triage Test (AdnexaSure™), a CE-marked/FDA-cleared blood test that distinguishes benign from malignant ovarian masses prior to surgery. The technology platform uses a proprietary algorithm combining the CXCL10 active ratio with multiple biomarkers (CA125, HE4, IL6) to generate Risk of Malignancy scores. CLEO's staged execution strategy encompasses multiple test products: the initial pre-surgical triage market, followed by recurrence monitoring and high-risk population tests, ultimately leading to an early-stage screening test for general population detection.

Differentiator

Problem solved

Functional benefit

Brands

  • AdnexaSure: CLEO's first test - AdnexaSure is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.

Products and services

  • AdnexaSure™ Pre-Surgical Triage Test A blood test (IVD kit) designed to accurately distinguish benign from malignant ovarian growths prior to surgical intervention. The test measures the CXCL10 active ratio combined with biomarkers including CA125, HE4, and IL6, processed on the Bio-Techne Ella™ automated ELISA platform, and returns a Risk of Malignancy score to the referring physician. It is intended for sale to clinical pathology laboratories and ordered by gynaecologists and oncologists.

Quantifiable outcome

  • 90% early-stage (Stage I/II) cancer detection vs 50% with standard CA125+ultrasound workflows
  • +5 more outcomes

Companies that use Cleo Diagnostics

Customer profile

Segments3 records

Ideal customer profiles2 records

Cleo Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature3 records

Cleo Diagnostics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, key and supporting.

  • Bio-Techne Corporation (NASDAQ: TECH)coreTechnology or Integration · 18 February 2026CLEO selected Bio-Techne's Ella™ automated ELISA platform as the immunoassay instrument for its ovarian cancer blood test. The Ella™ platform uses microfluidic cartridges to measure CLEO's proprietary biomarker panel. Discussions are well progressed for a binding agreement for analytical validation. Both parties are aligned to enter a long-term manufacturing supply agreement following completion of validation activities. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025.
  • EntityRiskkeyImplementation/ SI/ Consulting Partner · 18 August 2025Specialist in health economics and value modelling engaged to develop a model quantifying the economic benefits of adopting CLEO's Pre-Surgical Test for Ovarian Cancer in the US. The health economic analysis will provide evidence-based justification for payor engagement and reimbursement negotiations.
  • Norstella (including MMIT)keyImplementation/ SI/ Consulting Partner · 18 August 2025Global pharma intelligence solution provider engaged to examine detailed physician and claims data to identify high-value US launch markets and maximise early adoption potential. Norstella's market access and payer intelligence capabilities (including Managed Markets Insight & Technology/MMIT) inform reimbursement data modelling. Comprehensive analysis delivers refined TAM estimate and payer policy insights.
  • National Cancer Institute (NCI) / PLCO Cancer Screening TrialcoreStrategic or Co-development Partner · 25 June 2025CLEO received formal approval from the US National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial biobank. The PLCO is considered a gold standard resource and one of the largest US longitudinal cancer studies. Samples will be used to generate data strengthening CLEO's FDA 510(k) submission and accelerate development of its screening test.
  • University College London (UCL)coreStrategic or Co-development Partner · 28 April 2025Collaboration agreement with UCL granted CLEO access to over 2,000 blood samples from the UKCTOCS (United Kingdom Collaborative Trial of Ovarian Cancer Screening), the world's largest ovarian cancer screening trial. Data will be independently analysed in partnership with UCL, providing unbiased validation of CLEO's technology. Partnership with renowned Ovarian Cancer expert Professor Usha Menon supports both pre-surgical and screening market evaluation.
  • R&D Systems, Inc. (subsidiary of Bio-Techne Corporation)coreTechnology or Integration · 18 March 2025R&D Systems, a global leader in immunoassay technology and subsidiary of Bio-Techne Group, was engaged to scale-up and assemble CLEO's proprietary antibodies for use in its initial Ovarian Cancer test targeted at the surgical triage market. The company undertook hybridoma cell line development, antibody production and testing, and reagent selection. This partnership represents the critical technology transfer step from in-house development to commercial-scale production.
  • Siles HealthsupportingStrategic or Co-development Partner · 10 December 2024Network of 13 women's health and ultrasound specialist clinics across Melbourne and regional Victoria joined CLEO's Australian ovarian cancer trial, with Associate Professor Charles Siles as Principal Investigator. Partnership aims to provide insights into clinical workflows supporting market adoption and supplement the broader trial strategy.
  • The Royal Women's Hospital MelbournesupportingStrategic or Co-development Partner · 27 November 2024Australia's leading specialist hospital for women's health joined CLEO's ovarian cancer trial as a participating site, with Associate Professor Orla McNally (Director of Oncology and Dysplasia Service) as Principal Investigator. Partnership aims to broaden patient sampling, expand market awareness, verify and optimise the ovarian cancer blood test, and potentially bolster the US trial.
  • Lindus HealthcoreImplementation/ SI/ Consulting Partner · 11 April 2024US-based Contract Research Organization (CRO) appointed to manage the successful execution of CLEO's ovarian cancer US clinical trials. Lindus Health was chosen for its proven experience, technology, and high standards in med-tech clinical trial management. The study targets up to 500 US patients with trial scheduled over 10 months. Lindus Health leverages innovative patient recruitment and trial management technology platform.
  • HcFocus (New York)coreImplementation/ SI/ Consulting Partner · 2 April 2024New York-based strategic healthcare consultancy appointed to assist with US commercial activities. HcFocus specialises in helping med-tech companies access the US healthcare market, supporting FDA approval, reimbursement with private insurers, clinical trial support, KOL appointments, and industry/doctor engagement. Led by Dr Susan Gross (Ob/GYN), the team brings deep US healthcare industry experience and networks.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Cleo Diagnostics competitors and assessment

Company assessment

Direct peers

  • Aspira Women's Health: Markets OVA1 and OVERA blood tests for pre-surgical triage of ovarian/adnexal masses — directly comparable to Cleo's AdnexaSure™ in the same indication, customer base (gynaecologists, pathologists) and clinical workflow.
  • Natera: Provides oncology and reproductive-health blood-based diagnostics (Signatera, Empower, Vistara), overlapping with Cleo on biomarker-driven blood tests targeting women's health and oncology specialists.

Broad incumbents

  • Myriad Genetics: Established hereditary and oncology diagnostics franchise (BRACAnalysis, MyChoice, Prolaris) sold through the same physician and pathology channels Cleo targets, providing both competitive pressure and a benchmark for women's-health oncology commercial models.
  • Exact Sciences: Commercial leader in non-invasive cancer screening (Cologuard, Oncotype DX) with a broad oncology diagnostics portfolio and US sales infrastructure that could credibly extend into ovarian cancer screening if Cleo's platform proves out.
  • Hologic: Large women's-health diagnostics and medical device company (ThinPrep, NovaSure, Panther molecular system) with established gynaecologist and pathology-lab relationships directly relevant to a pre-surgical ovarian triage launch.
  • NeoGenomics: Oncology-focused clinical laboratory services business with broad oncologist and pathology-lab relationships; a potential commercial channel and indirect competitor in oncology diagnostics workflows.

Emerging players

  • Guardant Health: Liquid-biopsy oncology testing franchise (Guardant360, Reveal) with overlapping biomarker-based blood-test technology and similar physician-channel go-to-market motion, though focused on genomic rather than proteomic signals.
  • GRAIL: Multi-cancer early-detection blood test (Galleri) pursuing a population-screening indication that is the downstream commercial endpoint of Cleo's stated pipeline strategy.
  • Freenome: Multiomics blood-based cancer screening developer with an overlapping biomarker-discovery and clinical-validation approach in oncology diagnostics.

Others

  • Bio-Techne: Technology and manufacturing partner providing the Ella™ automated ELISA platform and antibody production services; not a competitor but a strategic dependency and enabling participant in Cleo's commercial pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cleo Diagnostics social profiles

Digital presence

Cleo Diagnostics compliance and trust

Trust signal

Compliance3 records

Cleo Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cleo Diagnostics leadership team

Management profile

Number of profiles

Profiles8 records

Cleo Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cleo Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cleo Diagnostics

What does Cleo Diagnostics do?

Cleo Diagnostics is developing and commercialising a proprietary blood-based diagnostic test (AdnexaSure™) for the early and accurate detection of ovarian cancer. The test uses the CXCL10 active ratio combined with additional biomarkers to generate a Risk of Malignancy score that distinguishes benign from malignant adnexal masses prior to surgery. The test is designed to be ordered and processed through standard clinical pathology laboratory workflows using the Bio-Techne Ella™ automated ELISA platform.

Is Cleo Diagnostics a public or private company?

Cleo Diagnostics is a public company. It is classified as public and is currently operating.

When was Cleo Diagnostics founded?

Cleo Diagnostics was founded in 2021. It employs 11 to 50 people.

Where is Cleo Diagnostics based?

Cleo Diagnostics is headquartered in Melbourne, Australia, in the Oceania region.

How does Cleo Diagnostics make money?

One revenue line is on record: diagnostic Test Kits.

Who are Cleo Diagnostics's main competitors?

Direct peers on record are Aspira Women's Health and Natera. Broad incumbents are Myriad Genetics, Exact Sciences, Hologic and NeoGenomics. Emerging players are Guardant Health, GRAIL and Freenome. Bio-Techne is listed as an others.

Does Cleo Diagnostics have an API?

No public API is recorded for Cleo Diagnostics.

What industry is Cleo Diagnostics in?

Cleo Diagnostics's product category is Ovarian Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCleo Diagnostics Exceeds Performance Targets in First PoC Study of Ovarian Cancer Screening TestCleo Diagnostics' prototype ovarian cancer screening test met and exceeded performance thresholds in a first proof-of-concept study of 247 women. The study achieved 92.2% sensitivity and 98.7% specificity for high-risk screening, and 75% sensitivity and 100% specificity for general population screening. Next-stage testing will be conducted on a larger independent cohort.TradingViewCleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood TestCleo Diagnostics will begin analytical validation of its pre-surgical ovarian cancer blood test after receiving the first production batch of 125 kits from Bio-Techne. The eight-biomarker assay includes three new biomarkers to improve reproducibility, and validation will precede clinical validation and an FDA 510(k) submission in FY27.AInvestCLEO Diagnostics Options Lapse: What Actually Happened and Why It MattersCLEO Diagnostics saw 8.45 million listed options expire unexercised on August 22, removing approximately 6% of potential dilution from its share base due to market illiquidity and transaction costs. Concurrently, director Lucinda Frawley exercised 1.5 million unlisted options, injecting $450,000 into the company. This event simplifies the capital structure but does not alter the company's ongoing cash burn rate or regulatory timeline for its ovarian cancer diagnostic product.TipranksCleo Diagnostics Director Restructures Holding via Super Fund TransferCleo Diagnostics director Thomas William Jobling transferred 1.5 million unlisted options from his personal holding to his associated superannuation fund, Marlar Investments Pty Ltd. Following this off-market transfer, Jobling retains an aggregate economic exposure of 1 million ordinary shares and 1.75 million options, with no change to his total interest in the company. This disclosure complies with ASX listing rules and Australian corporate regulations.MarketScreenerCleo Diagnostics Ltd Reports Earnings Results for the Full Year Ended June 30, 2026Cleo Diagnostics Ltd reported earnings results for the full year ended June 30, 2026. The company focuses on developing a blood test for the early detection of ovarian cancer based on the CXCL10 biomarker. This report serves as a standard financial disclosure for the healthcare diagnostics firm.TipranksCleo Diagnostics Posts Deeper Annual Loss as Revenue Falls and Asset Backing WeakensCleo Diagnostics Limited reported a 31.6% decline in revenue to $232,352 and a 48.4% increase in net loss to $5,936,480 for its 2026 financial year. The company's net tangible assets per share decreased to 3.43 cents from 4.26 cents, reflecting an erosion of balance-sheet value despite receiving an unmodified audit opinion. No dividends were declared as the firm continues to focus on funding operations and development.KalkineCLEO Diagnostics (ASX:COV) Is Under Pressure. Here’s a Possible ExplanationShares of CLEO Diagnostics fell on the Australian stock market as investors monitored the progress of its ovarian cancer diagnostic test. The decline reflects the typical milestone-driven volatility of development-stage biotech companies rather than a specific confirmed operational setback. Market attention remains focused on upcoming validation data, regulatory milestones, and broader biotech sentiment.TipranksCleo Diagnostics Secures $5M for U.S. Launch and Screening DevelopmentCleo Diagnostics Ltd announced a successful A$5 million capital raise to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and expedite development of a mass ovarian cancer screening test. The funding round introduced new institutional investors, signaling market endorsement of CLEO's CXCL10 biomarker-based diagnostic technology. The company, currently valued at A$88.02 million, is positioned to advance its ovarian cancer diagnostic roadmap which includes pre-surgical testing, recurrence monitoring, and global screening solutions.MarketScreenerCleo Diagnostics Raises AU$5 Million via Placement; Shares Fall 6%Cleo Diagnostics Limited has raised AU$5 million through a placement to support its ovarian cancer blood test development program based on the CXCL10 biomarker. The company's shares fell 6% following the announcement, likely reflecting dilution concerns from the capital raise. Cleo Diagnostics is advancing three related tests for ovarian cancer detection: a Triage Test, a Recurrence Test, and a Screening Test.Biotech DispatchCleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screeningCleo Diagnostics has raised $5 million through a placement of 8.33 million shares at $0.60 per share to institutional and high-net-worth investors, with Petra Capital acting as lead manager. The Melbourne-based company's funds will support the commercial launch of its Pre-Surgical Ovarian Cancer Test in the US and accelerate development of a mass screening test for ovarian cancer. CEO Dr Richard Allman described the placement as a critical inflection point enabling the company to expand into the US market while advancing its diagnostic pipeline.